Bayer advances fight against rare kidney disease with new experimental drug

Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes

Denali clinches $275 million royalty deal to power potential breakthrough Hunter Syndrome therapy

Paradigm Health to acquire Flatiron’s clinical research business

It's an acquisition that aims at forming one of the US's largest oncology trial networks

Biocon to merge Biocon Biologics in $5.5 billion deal

Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million

Bristol Myers Squibb secures FDA nod for Breyanzi in marginal zone lymphoma

The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population

Lupin inks US licensing deal with Valorum for biosimilar Armlupeg

Valorum will advance the commercialization and distribution of Armlupeg in the United States

Terray Therapeutics hits milestone in collaboration with Bristol Myers Squibb

Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities

Excelsior Sciences raises $95 million for drug discovery with AI-ready chemistry

Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions

Eli Lilly pledges $40 million to Indiana University to expand clinical trials

The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy

Wellcome injects £2 million to turbocharge UK regulation of digital mental health tech